Heart failure related to pulmonary arterial hypertension (PAH) is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue, with more cases and deaths expected by 2050, a study showed. In the three decades from 1990 to 2021, women accounted for more…
News
Pulmonary artery denervation (PADN), a procedure that targets overactive nerves involved in blood vessel constriction, significantly lessens high blood pressure in the lungs of people with pulmonary hypertension (PH), according to a meta-analysis of more than a dozen studies. Pooled data also showed that the approach was associated with…
Treatments approved for pulmonary arterial hypertension (PAH) may reduce by half the risk of serious complications or death in adults and adolescents who also have repaired congenital heart disease (CHD), pooled data analysis of three clinical trials shows. This risk was similarly reduced among the whole PAH patient population…
Corvista Health’s point-of-care device, which can be used to predict pulmonary hypertension in a noninvasive way, also appears to work well at identifying heart failure, accurately detecting patients who have it while ruling it out in others, a study found. Using machine learning to decode data from patients,…
The advocacy organization Phaware is launching a series of podcasts to explore new advances in the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The series will be launched as part of “I’m Aware That I’m Rare: the phaware podcast,” which can be found online…
Treatment with the approved therapy Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with pulmonary arterial hypertension (PAH), according to results from the Phase 3 ZENITH clinical trial. Findings were published in The New England Journal of Medicine, in the study, “…
The U.S. Food and Drug Administration (FDA) is poised to soon issue a final determination on Yutrepia, an inhaled dry powder formulation of treprostinil, up for approval to treat both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The FDA granted Yutrepia…
Pulmonary hypertension (PH) is associated with an increased risk for sleep disorders, including obstructive sleep apnea, and structural brain changes at the genetic level, according to a recent study. These findings may help “develop new guidelines for the clinical management, personalized diagnosis, and treatment of PH, sleep disorder…
A higher diameter and a faster enlargement rate of the body’s main pulmonary artery — dubbed the MPA, it carries oxygen-poor blood out of the heart toward the lungs — are independent predictors of poor outcomes among people with pulmonary arterial hypertension (PAH), a new study reports. In predicting…
A higher diameter ratio on CT scans between the right ventricle and left ventricle, which are the heart’s lower chambers, independently predicts major adverse cardiovascular events in people with pulmonary hypertension (PH), a study reports. “In our study, the [right ventricle/left ventricle] ratio not only well reflected PH severity,…
Researchers in the U.S. have developed a tool to help predict mortality risk in people with chronic lung disease and pulmonary hypertension (PH). The tool, PVD-B65, accounts for risk factors related to both conditions, including age, lung disease type, PH severity, exercise capacity, and blood levels of a heart…
Corsair Pharma successfully completed preclinical studies testing its skin patch delivery system for treprostinil as a treatment for pulmonary arterial hypertension (PAH), and is now planning to launch a Phase 1 clinical trial in the next few months. That’s according to new updates from the U.S.-based company, which…
